Dear All,
I am trying to compile a response to the new NICE ACD for IM intolerance and would be grateful if those of you who have any or all of the following would contact me before tomorrow:
a. experienced grade 3/4 adverse effects of any kind
b. have haematological intolerance to IM (i.e blood counts drop to worrying/dangerous levels)
c. due to intolerance are now treated with 2nd generation drug
Please contact me as soon as possible with an outline of your story...... and also let me know if you are willing to talk to media etc.
As you are aware, NICE have separated off the two patient populations which means that iM resistance will be appraised at some future date as part of the TA70 reappraisal of imatinib. That might be seen as good news for resistant patients, but I must admit I remain cautious in my optimism.
However, the urgent issue now is that we have to focus on the new ACD for IM intolerance and my thinking on this is:
* the issue of inequity remains
* intolerance - haematological adverse effects- can be life threatening
* intolerance can mean that IM can only be given in a 'sub-optimal' dose supported by other drugs to support marrow function (GCSF)
* intolerance can be 'intolerable' and adversely affect quality of life
There is at least one other anomaly contained in the NICE response that I cannot go into here just yet but just to put this all this into context the cost to the NHS of funding either one of the 2nd generation drugs for IM 'intolerance' would be:
* The likely number of intolerant patients per year -approx 35 multiplied by the acquisition cost of either drug to the NHS -both just over £30-31,000 =
£1,850,000.00 per year....... ! Think about it. (sorry, noughts in wrong place- this figure should be £1,085,000.00)
I would really appreciate your support. There is rather a tight deadline for me to compile a well argued response.
Sandy